Actualités

Aug 3 (Reuters) - U.S. stock index futures edged higher on Monday as signs of de-escalating tensions in the Middle East weighed on crude prices, while investors prepared for another week packed with

The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion.

The funding will advance its ATLAS trial, assessing lead candidate [Ac-225]RTX-2358, a FAP-targeted radiotherapeutic for advanced sarcomas.

↗️↘️AstraZeneca (AZN, UK:AZN), Bristol Myers Squibb (BMY): The drug companies are in talks to combine in a deal that would value the joint company at roughly $400 billion, the Financial Times reported.

U.S. stocks were on track to extend Friday’s rally as President Trump said he had canceled planned strikes on Iran, adding that peace talks would resume Monday afternoon.

Reports indicate AstraZeneca and Bristol-Myers Squibb are in early talks regarding a potential merger. If agreed, the combined group would rank among the largest pharmaceutical companies globally. The discussions are described as preliminary and no formal deal has been announced as at 31 July 2026. Bristol-Myers Squibb, traded as NYSE:BMY, is back in focus as investors consider what a tie up with AstraZeneca could mean for the $65.31 share price. The stock has logged returns of 5.2% over...

If maintained until close, the decline would be the stock’s biggest one-day percentage fall since the day of the 2024 U.S. presidential election.

Shares in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) fell 7% to 11,723p on Monday after news that Britain's biggest drugmaker is in talks to buy its US rival, Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP). A deal would create a pharmaceutical group worth close to $400 billion, ranking...

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

8.31am: AstraZeneca talks suggest 'reduced confidence' in outlook AstraZeneca's reported talks with Bristol Myers about creating a $400 billion company appear to make "limited strategic sense for Astra and would likely be subject to antitrust scrutiny, given the overlaps of their oncology...

A potential AstraZeneca-Bristol Myers deal worth $400 billion would create one of the world’s largest drugmakers and combine major cancer franchises.

By Sabrina Valle and Michael Erman Aug 2 (Reuters) - AstraZeneca Plc and Bristol Myers Squibb held preliminary discussions about a possible combination that would create one of the world's biggest

Aug 2 () - UK drugmaker AstraZeneca has been exploring a deal to combine with U. rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter.

Investing.com -- AstraZeneca PLC (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) have held talks in recent months about a deal that would combine the companies into one, according to a Financial Times report.

AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb in a deal likely to raise fresh questions over the company’s ties to the UK.

AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb in a deal likely to raise fresh questions over the company’s ties to the UK.

Bristol Myers Squibb's P/E ratio is below the industry average, but you have to take this key fact into consideration before buying it.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on year to $12.97 billion. The company’s full-year revenue guidance of $49.5 billion at the midpoint came in 4.3% above analysts’ estimates. Its non-GAAP profit of $2.04 per share was 27.7% above analysts’ consensus estimates.

Bristol Myers Squibb (NYSE:BMY) reported second-quarter 2026 revenue of approximately $13 billion, up 5% from a year earlier, as growth in newer products offset declines across its legacy portfolio. The company raised its full-year revenue and adjusted diluted earnings-per-share guidance, citing fir

CorpGov hosted a fireside chat on July 28 from the floor of the New York Stock Exchange with Gabriel Hasson, Global Head of Governance, Shareholder and Activism Advisory, Managing Director at ICR. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed the back to fundamentals for corporate governance as shareholder activism reaches […] The post Activist Investors Shift Back to Basics: ICR Global Head of Governance Gabriel Hasson, Live at NYSE appeared first on Co

Bristol-Myers Squibb (BMY) delivered a strong Q2 but is experiencing slight delays to the launches o

AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution

BMY highlights growth portfolio momentum, raises 2026 outlook and advances pipeline priorities as newer medicines drive results.

Companies in The News Are: MA,BMY,MO,REGN

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

Bristol-Myers Squibb (BMY) reported second quarter 2026 results that exceeded Wall Street expectations, with revenue and earnings per share ahead of forecasts and management raising full year guidance for both measures. See our latest analysis for Bristol-Myers Squibb. The strong Q2 surprise has come on top of an already solid run for Bristol-Myers Squibb, with a 1-month share price return of 12.57% and a year to date share price return of 21.32%. Over a longer horizon, total shareholder...

Moby summary of Bristol-Myers Squibb Company's Q2 2026 earnings call

Growth portfolio now drives 60% of revenue as Eliquis surges 21%.

It notched convincing beats on analyst estimates with its second-quarter performance.

Strong revenue growth driven by Eliquis and key growth assets, offset by Opdivo decline and delayed readouts for Milvexian and Cobenfy.